9.02
0.32%
-0.05
Schlusskurs vom Vortag:
$8.97
Offen:
$9.04
24-Stunden-Volumen:
49,807
Relative Volume:
0.06
Marktkapitalisierung:
$478.78M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-9.5957
EPS:
-0.94
Netto-Cashflow:
$-33.83M
1W Leistung:
-0.98%
1M Leistung:
+4.70%
6M Leistung:
+93.54%
1J Leistung:
+98.26%
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Firmenname
Zevra Therapeutics Inc
Sektor
Branche
Telefon
(321) 939-3416
Adresse
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Vergleichen Sie ZVRA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
ZVRA | 9.005 | 478.78M | 27.46M | -46.05M | -33.83M | -0.94 |
VRTX | 447.18 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.71 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.84 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.36 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-03-17 | Eingeleitet | Maxim Group | Buy |
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
HC Wainwright Expects Lower Earnings for Zevra Therapeutics - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Guggenheim Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy Recommendation - MSN
Zevra Therapeutics (STU:1GDA) Enterprise Value : €424.12 Mil (As of Nov. 20, 2024) - GuruFocus.com
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily
ZVRA FY2024 EPS Forecast Decreased by Cantor Fitzgerald - MarketBeat
What is William Blair's Forecast for ZVRA FY2024 Earnings? - MarketBeat
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report - Yahoo Finance
Zevra testing beta blocker celiprolol for vEDS in Phase 3 US study - Ehlers-Danlos News
Simplify Asset Management Inc. Invests $833,000 in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
What is William Blair's Estimate for ZVRA FY2026 Earnings? - MarketBeat
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results - Simply Wall St
Roth Capital Forecasts Lower Earnings for Zevra Therapeutics - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Decline in Short Interest - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Zevra Therapeutics reports Q3 financial results - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Given New $23.00 Price Target at Canaccord Genuity Group - MarketBeat
Q4 Earnings Forecast for ZVRA Issued By Roth Capital - MarketBeat
Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com
Janney Montgomery Scott LLC Sells 127,755 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - GuruFocus.com
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance
Zevra Therapeutics’ Transformative Third Quarter 2024 - TipRanks
Zevra Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Zevra Therapeutics earnings missed by $0.28, revenue fell short of estimates - Investing.com UK
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
Zevra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... By GuruFocus - Investing.com Canada
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting - The Manila Times
Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Kn - GuruFocus.com
Zevra Therapeutics Validates Key Clinical Scale for Niemann-Pick Disease Treatment Study | ZVRA Stock News - StockTitan
International Assets Investment Management LLC Raises Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ZVRA stock touches 52-week high at $8.96 amid market rally - Investing.com India
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $20.83 Average PT from Analysts - MarketBeat
Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 - The Manila Times
Zevra Therapeutics CEO to Present at Guggenheim Healthcare Conference | ZVRA Stock News - StockTitan
Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Zevra Therapeutics Inc - GuruFocus.com
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 - The Manila Times
Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline - Yahoo Finance
How To Trade (ZVRA) - Stock Traders Daily
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals - BioCentury
Will Zevra Gallop Or Saunter In Q3? - RTTNews
Objective long/short (ZVRA) Report - Stock Traders Daily
Sanctuary Advisors LLC Makes New $474,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra therapeutics director Corey Watton buys $3,957 in stock - Investing.com India
Zevra therapeutics director Corey Watton buys $3,957 in stock By Investing.com - Investing.com Australia
Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN
Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zevra Therapeutics Inc-Aktie (ZVRA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Clifton R. LaDuane | CFO & Treasurer |
Jul 17 '24 |
Buy |
6.77 |
2,000 |
13,540 |
18,469 |
Anderson Thomas | Director |
Jul 16 '24 |
Buy |
6.81 |
10,000 |
68,065 |
20,000 |
Bode John B | Director |
Jul 12 '24 |
Buy |
5.87 |
10,000 |
58,661 |
30,000 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):